The UK Medicines and Healthcare products Regulatory Agency authorized Onswik, or insulin efsitora alfa, on October 13 for adults with type 2 diabetes. The long-acting basal insulin is injected once weekly and may reduce basal-insulin dosing for some patients from once daily, or as many as 365 injections a year, to 52. The MHRA says clinical-trial data showed glycaemic control comparable to once-daily basal insulin. NICE has issued final draft guidance recommending it for certain adults subject to authorization, a condition now met. Hypoglycaemia is the most common adverse reaction. The drug will not suit every patient and cannot replace clinician-led decisions based on glucose, complications and individual risk; long-term safety monitoring will continue after launch.